Close Asset Management’s BioNTech BNTX Stock Holding History

Close Asset Management’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6K	Hold	61	–	–	﹤0.01%	241
2026 Q1	$5K	Hold	61	–	–	﹤0.01%	243
2025 Q4	$6K	Hold	61	–	–	﹤0.01%	238
2025 Q3	$6K	Buy	+61	New	+$6.52K	﹤0.01%	241

Other funds holding BNTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

GSK plc London $602M AUM

Close Asset Management's BNTX Position: Q2 2026 in Review

Close Asset Management held its BioNTech (BNTX) position steady in Q2 2026 at 61 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #241.

Close Asset Management first reported a position in BNTX in Q3 2025 and has held it in 4 quarters since. 283 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

Close Asset Management held 61 shares of BioNTech worth $6K as of Q2 2026.
Close Asset Management left its BioNTech share count unchanged in Q2 2026.
BioNTech made up ﹤0.01% of Close Asset Management's portfolio in Q2 2026, its #241 holding.
Close Asset Management first reported a position in BioNTech in Q3 2025 and has held it in 4 quarters since.
283 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on Close Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.